Efficacy and safety of puerarin injection as an adjunctive therapy for chronic heart failure: a systematic review and meta-analysis

ObjectivePuerarin injection is used for the treatment of chronic heart failure (CHF). The objective of this study is to investigate the efficacy and safety of puerarin injection as an adjunct therapy for CHF through a meta-analysis and systematic review.MethodsWe conducted a comprehensive literature...

Full description

Saved in:
Bibliographic Details
Main Authors: Hesong Fan, Jingrong Yang, Huaizhe Wang, Shuli Zong, Yiwei Qu, Kefei Wang, Fengyi Zhang, Xiao Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1516059/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849314888568012800
author Hesong Fan
Jingrong Yang
Huaizhe Wang
Shuli Zong
Yiwei Qu
Kefei Wang
Fengyi Zhang
Xiao Li
author_facet Hesong Fan
Jingrong Yang
Huaizhe Wang
Shuli Zong
Yiwei Qu
Kefei Wang
Fengyi Zhang
Xiao Li
author_sort Hesong Fan
collection DOAJ
description ObjectivePuerarin injection is used for the treatment of chronic heart failure (CHF). The objective of this study is to investigate the efficacy and safety of puerarin injection as an adjunct therapy for CHF through a meta-analysis and systematic review.MethodsWe conducted a comprehensive literature search across eight databases, including PubMed, Embase, Web of Science, and Cochrane Library, up to 1 March 2025, to identify the required randomized controlled trials (RCTs). Subsequently, we assessed the included studies according to the principles outlined in the Cochrane Handbook and performed a meta-analysis using RevMan 5.4 and Stata 12.0.ResultsA total of 29 RCTs were included, comprising 2,480 patients, with 1,251 in the Puerarin group and 1,229 in the control group. The meta-analysis demonstrated that puerarin injection combined with conventional medication significantly improved cardiac function parameters in chronic heart failure patients compared to pharmacotherapy alone, including left ventricular ejection fraction (MD = 6.22, 95% CI [3.11, 9.33], P < 0.01), cardiac output (MD = 0.45, 95% CI [0.35, 0.55], P < 0.01), and stroke volume (MD = 3.29, 95% CI [2.02, 4.57], P < 0.01), while reducing left ventricular end-diastolic diameter (MD = −0.83, 95% CI [−1.24, −0.42], P < 0.01). The combination therapy demonstrated both a significantly increased total effectiveness rate (RR = 1.26, 95% CI [1.21, 1.31], P < 0.01) and improved hemodynamic parameters, along with favorable modulation of oxidative stress markers evidenced by elevated superoxide dismutase, glutathione peroxidase, and catalase levels concomitant with reduced lipid peroxidation and malondialdehyde concentrations.ConclusionThis meta-analysis suggests that adjunctive puerarin injection with conventional therapy may provide comprehensive benefits for chronic heart failure management, including improved clinical outcomes, enhanced cardiac function, attenuated ventricular remodeling, optimized hemodynamic performance, and reduced oxidative stress, while maintaining a safety profile comparable to conventional therapy. However, due to the suboptimal quality and some degree of heterogeneity in the existing evidence, there is a need for more high-quality studies to provide more reliable evidence for its future clinical application.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD42022371583.
format Article
id doaj-art-613ea7641cd84edfadda3123beea3cea
institution Kabale University
issn 1663-9812
language English
publishDate 2025-04-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj-art-613ea7641cd84edfadda3123beea3cea2025-08-20T03:52:16ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-04-011610.3389/fphar.2025.15160591516059Efficacy and safety of puerarin injection as an adjunctive therapy for chronic heart failure: a systematic review and meta-analysisHesong Fan0Jingrong Yang1Huaizhe Wang2Shuli Zong3Yiwei Qu4Kefei Wang5Fengyi Zhang6Xiao Li7First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, ChinaFirst Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, ChinaFirst Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, ChinaFirst Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, ChinaFirst Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, ChinaFirst Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, ChinaFirst Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, ChinaAffiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, ChinaObjectivePuerarin injection is used for the treatment of chronic heart failure (CHF). The objective of this study is to investigate the efficacy and safety of puerarin injection as an adjunct therapy for CHF through a meta-analysis and systematic review.MethodsWe conducted a comprehensive literature search across eight databases, including PubMed, Embase, Web of Science, and Cochrane Library, up to 1 March 2025, to identify the required randomized controlled trials (RCTs). Subsequently, we assessed the included studies according to the principles outlined in the Cochrane Handbook and performed a meta-analysis using RevMan 5.4 and Stata 12.0.ResultsA total of 29 RCTs were included, comprising 2,480 patients, with 1,251 in the Puerarin group and 1,229 in the control group. The meta-analysis demonstrated that puerarin injection combined with conventional medication significantly improved cardiac function parameters in chronic heart failure patients compared to pharmacotherapy alone, including left ventricular ejection fraction (MD = 6.22, 95% CI [3.11, 9.33], P < 0.01), cardiac output (MD = 0.45, 95% CI [0.35, 0.55], P < 0.01), and stroke volume (MD = 3.29, 95% CI [2.02, 4.57], P < 0.01), while reducing left ventricular end-diastolic diameter (MD = −0.83, 95% CI [−1.24, −0.42], P < 0.01). The combination therapy demonstrated both a significantly increased total effectiveness rate (RR = 1.26, 95% CI [1.21, 1.31], P < 0.01) and improved hemodynamic parameters, along with favorable modulation of oxidative stress markers evidenced by elevated superoxide dismutase, glutathione peroxidase, and catalase levels concomitant with reduced lipid peroxidation and malondialdehyde concentrations.ConclusionThis meta-analysis suggests that adjunctive puerarin injection with conventional therapy may provide comprehensive benefits for chronic heart failure management, including improved clinical outcomes, enhanced cardiac function, attenuated ventricular remodeling, optimized hemodynamic performance, and reduced oxidative stress, while maintaining a safety profile comparable to conventional therapy. However, due to the suboptimal quality and some degree of heterogeneity in the existing evidence, there is a need for more high-quality studies to provide more reliable evidence for its future clinical application.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD42022371583.https://www.frontiersin.org/articles/10.3389/fphar.2025.1516059/fullpuerarin injectionchronic heart failuremeta-analysissystematic reviewtraditional Chinese medicine
spellingShingle Hesong Fan
Jingrong Yang
Huaizhe Wang
Shuli Zong
Yiwei Qu
Kefei Wang
Fengyi Zhang
Xiao Li
Efficacy and safety of puerarin injection as an adjunctive therapy for chronic heart failure: a systematic review and meta-analysis
Frontiers in Pharmacology
puerarin injection
chronic heart failure
meta-analysis
systematic review
traditional Chinese medicine
title Efficacy and safety of puerarin injection as an adjunctive therapy for chronic heart failure: a systematic review and meta-analysis
title_full Efficacy and safety of puerarin injection as an adjunctive therapy for chronic heart failure: a systematic review and meta-analysis
title_fullStr Efficacy and safety of puerarin injection as an adjunctive therapy for chronic heart failure: a systematic review and meta-analysis
title_full_unstemmed Efficacy and safety of puerarin injection as an adjunctive therapy for chronic heart failure: a systematic review and meta-analysis
title_short Efficacy and safety of puerarin injection as an adjunctive therapy for chronic heart failure: a systematic review and meta-analysis
title_sort efficacy and safety of puerarin injection as an adjunctive therapy for chronic heart failure a systematic review and meta analysis
topic puerarin injection
chronic heart failure
meta-analysis
systematic review
traditional Chinese medicine
url https://www.frontiersin.org/articles/10.3389/fphar.2025.1516059/full
work_keys_str_mv AT hesongfan efficacyandsafetyofpuerarininjectionasanadjunctivetherapyforchronicheartfailureasystematicreviewandmetaanalysis
AT jingrongyang efficacyandsafetyofpuerarininjectionasanadjunctivetherapyforchronicheartfailureasystematicreviewandmetaanalysis
AT huaizhewang efficacyandsafetyofpuerarininjectionasanadjunctivetherapyforchronicheartfailureasystematicreviewandmetaanalysis
AT shulizong efficacyandsafetyofpuerarininjectionasanadjunctivetherapyforchronicheartfailureasystematicreviewandmetaanalysis
AT yiweiqu efficacyandsafetyofpuerarininjectionasanadjunctivetherapyforchronicheartfailureasystematicreviewandmetaanalysis
AT kefeiwang efficacyandsafetyofpuerarininjectionasanadjunctivetherapyforchronicheartfailureasystematicreviewandmetaanalysis
AT fengyizhang efficacyandsafetyofpuerarininjectionasanadjunctivetherapyforchronicheartfailureasystematicreviewandmetaanalysis
AT xiaoli efficacyandsafetyofpuerarininjectionasanadjunctivetherapyforchronicheartfailureasystematicreviewandmetaanalysis